Navigation Links
The Leukemia & Lymphoma Society Offers Crucial Help at a Critical Time
Date:2/26/2008

LLS's Insurance Co-Pay Assistance Program Provides Financial Support for

Prescriptions, Health Insurance Co-Pays

WHITE PLAINS, N.Y., Feb. 26 /PRNewswire/ -- The lymphoma diagnosis was terrifying enough. But when Charlotte Kostakos, 75, and her husband, Steven, 74, began struggling with the spiraling costs of paying for her treatments, they were overwhelmed.

"As far as we're concerned our income is Social Security, period, and therefore we were extremely anxious," said Steven. Still reeling from the shock of learning that Charlotte had B-cell lymphoma, the Kostakos's, who live part of the year in Claremont, Fla., and the other half in Edgarton, Wis., couldn't imagine how they would manage the costs, even with Medicare coverage.

The Kostakos's turned to The Leukemia & Lymphoma Society's co-pay assistance program for help.

"I don't know where we'd be without this program -- it's been a huge help to us," Steven said. "Every little bit that we can get is a relief for us."

The program provides support for prescription drug co-pays and health insurance premiums for patients who meet certain income requirements. Since launching the program last year, LLS has expanded it to include more disease categories. The program currently covers patients with Hodgkin lymphoma, non- Hodgkin lymphoma, chronic lymphocytic leukemia, waldenstrom macroglobulinemia, acute myelogenous leukemia, myeloma and myelodysplastic syndromes.

Patients with private insurance, Medicare beneficiaries under Medicare Part B and/or Medicare Plan D, Medicare Supplementary Health Insurance and Medicare Advantage premium are eligible.

"Receiving a diagnosis of a blood cancer is overwhelming and that devastating news can be compounded by an inability to afford the treatments," said Anita Welborn, director, LLS's Information Resource Center, and administrator of the program. "LLS is trying to do what it can to help alleviate this burden for the neediest patients that it serves."

For more information, visit http://www.lls.org/copay or call 877-LLS-COPAY.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. LLS's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call LLS's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact:

Andrea Greif, 914.821.8958

Andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Designers Young Cousin Inspiration Behind Colorful School and Office Supplies That Raise Awareness for Leukemia
2. The Leukemia & Lymphoma Society and the Nations Triathlon Announce New Partnership
3. Sorafenib Slows Growth of Some Leukemias
4. Kidney cancer drug attacks a major type of acute myeloid leukemia
5. Study Gets Closer to Origins of Leukemia
6. Molecules might identify high-risk acute-leukemia patients
7. VIDEO from Medialink and The Leukemia & Lymphoma Society: Saving Lives One Mile at a Time
8. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
9. Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
10. New drug candidate knocks out resistant form of chronic myeloid leukemia
11. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: